Abstract:Purpose Sirtuin7 (SIRT7), as a member of the sirtuin and NAD + -dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein–protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling. Methods USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student’s t test (two-tailed unpaired) and χ 2 test. Results We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer. Conclusion Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.

The Deubiquitinase Usp36 Regulates Dna Replication Stress And Confers Therapeutic Resistance Through Primpol Stabilization

USP37 Regulates DNA Damage Response Through Stabilizing and Deubiquitinating BLM

USP1-dependent nucleolytic expansion of PRIMPOL-generated nascent DNA strand discontinuities during replication stress

USP39 Regulates DNA Damage Response and Chemo-Radiation Resistance by Deubiquitinating and Stabilizing CHK2.

USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response

USP13 regulates the replication stress response by deubiquitinating TopBP1

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

USP50 suppresses alternative RecQ helicase use and deleterious DNA2 activity during replication

Human CST complex restricts excessive PrimPol repriming upon UV induced replication stress by suppressing p21

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells

The dePARylase NUDT16 promotes radiation resistance of cancer cells by blocking SETD3 for degradation via reversing its ADP-ribosylation

A Selective USP1–UAF1 Inhibitor Links Deubiquitination to DNA Damage Responses

USP52 Regulates DNA End Resection and Chemosensitivity Through Removing Inhibitory Ubiquitination from CtIP

A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.

The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage

Structure and Mechanism of Human DNA Polymerase Η

Proteome-wide Analysis of SUMO2 Targets in Response to Pathological DNA Replication Stress in Human Cells.

USP25 Elevates SHLD2‐Mediated DNA Double‐Strand Break Repair and Regulates Chemoresponse in Cancer

USP37 prevents unscheduled replisome unloading through MCM complex deubiquitination

USP37 protects mammalian cells during DNA replication stress by counteracting CUL2 and TRAIP